{
    "ticker": "LOGC",
    "name": "LogicBio Therapeutics, Inc.",
    "description": "LogicBio Therapeutics, Inc. is a pioneering biotechnology company focused on developing genetic therapies for rare diseases. Founded in 2014 and headquartered in Lexington, Massachusetts, LogicBio is committed to advancing the field of genome editing and gene therapy through its innovative platform technology, GeneRide\u2122, which facilitates the precise integration of therapeutic genes into the genome. This approach aims to provide lasting treatments for genetic disorders, including those affecting the liver, muscle, and central nervous system. LogicBio is particularly focused on developing therapies for conditions such as methylmalonic acidemia (MMA) and other inherited metabolic disorders. The company collaborates with leading academic institutions and industry partners to expand its research and development capabilities, ensuring that it remains at the forefront of genetic medicine. With a strong pipeline of product candidates, LogicBio is dedicated to addressing the unmet medical needs of patients with rare genetic diseases, offering hope for more effective and sustainable treatment options.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Lexington, Massachusetts, USA",
    "founded": "2014",
    "website": "https://www.logicbio.com",
    "ceo": "Fred Chereau",
    "social_media": {
        "twitter": "https://twitter.com/LogicBioTx",
        "linkedin": "https://www.linkedin.com/company/logicbio-therapeutics/"
    },
    "investor_relations": "https://investors.logicbio.com",
    "key_executives": [
        {
            "name": "Fred Chereau",
            "position": "CEO"
        },
        {
            "name": "David L. Kessler",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "LB-001",
                "LB-301"
            ]
        }
    ],
    "seo": {
        "meta_title": "LogicBio Therapeutics, Inc. | Innovative Genetic Therapies for Rare Diseases",
        "meta_description": "Explore LogicBio Therapeutics, Inc., a leader in genetic therapies for rare diseases. Learn about our innovative GeneRide\u2122 technology and product pipeline.",
        "keywords": [
            "LogicBio",
            "Gene Therapy",
            "Genetic Disorders",
            "Biotechnology",
            "Rare Diseases",
            "GeneRide"
        ]
    },
    "faq": [
        {
            "question": "What does LogicBio specialize in?",
            "answer": "LogicBio specializes in developing genetic therapies for rare diseases using its GeneRide\u2122 technology."
        },
        {
            "question": "Who is the CEO of LogicBio?",
            "answer": "Fred Chereau is the CEO of LogicBio Therapeutics, Inc."
        },
        {
            "question": "Where is LogicBio headquartered?",
            "answer": "LogicBio is headquartered in Lexington, Massachusetts, USA."
        },
        {
            "question": "What are some of LogicBio's product candidates?",
            "answer": "LogicBio's product candidates include LB-001 for methylmalonic acidemia and LB-301 for other genetic disorders."
        },
        {
            "question": "When was LogicBio founded?",
            "answer": "LogicBio was founded in 2014."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "ALNY",
        "VRTX"
    ]
}